1. Generics Bulletin
  2. >>Products

Momenta And Mylan Make Strides On Aflibercept

Partners Are Aiming For Market Entry In 2023

 
• By Dean Rudge

Having largely shelved the firms' global biosimilars collaboration that kicked off early in 2016, Momenta and Mylan are still working towards bringing a biosimilar to the Eylea blockbuster to the US, which currently has a market worth valued at more than $4.5bn.

Stairs
Momenta and Mylan are continuing to eye entry for a biosimilar to Eylea • Source: Shutterstock

With a pivotal clinical trial ongoing, Mylan is targeting a US filing next year for the biosimilar to Regeneron’s Eylea (aflibercept) that it is developing with Momenta, as part of plans to enter the market in 2023.

A dosing study comparing the safety, efficacy and immunogenicity of the firms’ M710 aflibercept biosimilar candidate in patients with diabetic macular edema kicked off in the US in August 2018; as well as

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims

 
• By Dean Rudge

Hikma said it would admit no wrongdoing or liability after reaching a preliminary settlement agreement over illicit ‘pay-for-delay’ claims involving its US version of Xyrem “that protects the company’s interests and provides clarity to our stakeholders.”

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Viatris Pens Aprepitant Settlement Agreement After Kabi Loses Initial Patent Case

 
• By Dean Rudge

Viatris will look to introduce generic versions of Heron Therapeutics’ aprepitant brands, Cinvanti and Aponvie, around three years before patent expiry after settling litigation with the originator. Other court cases remain ongoing.